brexu-cel
7 abstracts
Abstract
Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells.Org: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Center for Cellular Immunotherapies, Department of Biostatistics, Epidemiology, and Informatics,
Abstract
Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.Org: CHU Rennes, Univ Rennes, Service d'hématologie clinique et thérapie cellulaire Hopital du Haut-Leveque CHU de Bordeaux, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg,
Abstract
Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL).Org: The Ohio State University, Division of Hematology, The Ohio State University, Department of Internal Medicine, The Ohio State University, College of Medicine,
Abstract
Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.Org: City of Hope National Medical Center, Center for International Blood and Marrow Transplant Research, University of North Carolina School of Medicine, Moffitt Cancer Center, Stanford University Hospital,
Abstract
Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma.Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.Org: Moffitt Cancer Center, University of Washington & Fred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center, CHU Rennes, Université Rennes,
Abstract
Characterizing outcomes in severe cytopenias by 3 months in BCMA and CD19 CAR-T cell therapies: A single institution experience.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Emory University School of Medicine, Biostatistics Shared Resource, Emory University, Atlanta, GA, USA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA,